{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:04:57Z","timestamp":1760299497128,"version":"3.40.5"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ejim.2017.01.001","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T14:01:16Z","timestamp":1483711276000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Antithrombotic treatment in anticoagulated atrial fibrillation patients undergoing percutaneous coronary intervention"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7203-0423","authenticated-orcid":false,"given":"Csaba Andr\u00e1s","family":"D\u00e9zsi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bal\u00e1zs Bence","family":"D\u00e9zsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00f6me Andr\u00e1s","family":"D\u00e9zsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejim.2017.01.001_bb0005","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/europace\/eut373","article-title":"A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry","volume":"16","author":"Lip","year":"2014","journal-title":"Europace"},{"issue":"1","key":"10.1016\/j.ejim.2017.01.001_bb0010","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/europace\/eut263","article-title":"Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events\u2014European Registry in Atrial Fibrillation (PREFER in AF)","volume":"16","author":"Kirchhof","year":"2014","journal-title":"Europace"},{"issue":"9","key":"10.1016\/j.ejim.2017.01.001_bb0015","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024964","article-title":"Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography","volume":"6","author":"Kralev","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ejim.2017.01.001_bb0020","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/eurheartj\/ehn579","article-title":"Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications","volume":"30","author":"Schmitt","year":"2009","journal-title":"Eur Heart J"},{"issue":"45","key":"10.1016\/j.ejim.2017.01.001_bb0025","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ejim.2017.01.001_bb0030","doi-asserted-by":"publisher","first-page":"e000382","DOI":"10.1161\/JAHA.113.000382","article-title":"New-onset atrial fibrillation is associated with cardiovascular events leading to death in a first time myocardial infarction population of 89 703 patients with long-term follow-up: a nationwide study","volume":"3","author":"Bang","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"20","key":"10.1016\/j.ejim.2017.01.001_bb0035","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)","year":"2012","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.ejim.2017.01.001_bb0040","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.ejim.2017.01.001_bb0045","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.ejim.2017.01.001_bb0050","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.ejim.2017.01.001_bb0055","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1161\/CIR.0b013e31823a5596","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"issue":"37","key":"10.1016\/j.ejim.2017.01.001_bb0060","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Authors\/Task Force members","year":"2014","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.ejim.2017.01.001_bb0065","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.01.001_bb0070","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nature06797","article-title":"Triggers, targets and treatments for thrombosis","volume":"451","author":"Mackman","year":"2008","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ejim.2017.01.001_bb0075","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.thromres.2011.03.011","article-title":"Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome?","volume":"128","author":"Skeppholm","year":"2011","journal-title":"Thromb Res"},{"issue":"8","key":"10.1016\/j.ejim.2017.01.001_bb0080","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1182\/blood-2002-03-0954","article-title":"Coagulation activation and long-term outcome in acute coronary syndromes","volume":"102","author":"Ardissino","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejim.2017.01.001_bb0085","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1253\/circj.CJ-09-0982","article-title":"Basic principles of platelet biology and clinical implications","volume":"74","author":"Angiolillo","year":"2010","journal-title":"Circ J"},{"issue":"11","key":"10.1016\/j.ejim.2017.01.001_bb0090","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ejim.2017.01.001_bb0095","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ejim.2017.01.001_bb0100","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1093\/eurheartj\/ehq326","article-title":"Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian study)","volume":"31","author":"Fox","year":"2010","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.ejim.2017.01.001_bb0105","doi-asserted-by":"publisher","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","article-title":"Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit","volume":"143","author":"Rothberg","year":"2005","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.ejim.2017.01.001_bb0110","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.amjcard.2007.01.052","article-title":"Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes","volume":"99","author":"Testa","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2017.01.001_bb0115","article-title":"Risk of long-term anticoagulation under sustained severe arterial hypertension: a translational study comparing warfarin and the new oral anticoagulant apixaban","author":"Pfeilschifter","year":"2016","journal-title":"J Cereb Blood Flow Metab"},{"issue":"16","key":"10.1016\/j.ejim.2017.01.001_bb0120","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"issue":"2 Suppl","key":"10.1016\/j.ejim.2017.01.001_bb0125","doi-asserted-by":"publisher","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.ejim.2017.01.001_bb0130","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch Intern Med"},{"issue":"22","key":"10.1016\/j.ejim.2017.01.001_bb0135","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, doubleblind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.ejim.2017.01.001_bb0140","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2017.01.001_bb0145","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ejim.2017.01.001_bb0155","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)","year":"2012","journal-title":"Eur Heart J"},{"issue":"9872","key":"10.1016\/j.ejim.2017.01.001_bb0160","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2017.01.001_bb0165","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejim.2017.01.001_bb0170","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.009353","article-title":"Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes an analysis from the prospective, randomized PLATO trial","volume":"129","author":"Steg","year":"2014","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.ejim.2017.01.001_bb0175","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","article-title":"Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation","volume":"61","author":"Sarafoff","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ejim.2017.01.001_bb0180","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.thromres.2014.10.016","article-title":"Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome","volume":"135","author":"Braun","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2017.01.001_bb0185","volume":"27","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.ejim.2017.01.001_bb0190","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ejim.2017.01.001_bb0195","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/ijcp.12147","article-title":"Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation","volume":"67","author":"Huber","year":"2013","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.ejim.2017.01.001_bb0200","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000515","article-title":"Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials","volume":"3","author":"Douxfils","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.ejim.2017.01.001_bb0205","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.amjmed.2013.12.005","article-title":"Myocardial ischemic events in \u2018real world\u2019 patients with atrial fibrillation treated with dabigatran or warfarin","volume":"127","author":"Larsen","year":"2014","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.ejim.2017.01.001_bb0210","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ejim.2017.01.001_bb0215","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11239-014-1096-z","article-title":"Apixaban and risk of myocardial infarction: meta-analysis of randomized controlled trials","volume":"40","author":"Tornyos","year":"2015","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"10.1016\/j.ejim.2017.01.001_bb0220","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/eurheartj\/eht428","article-title":"Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial","volume":"35","author":"Mahaffey","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ejim.2017.01.001_bb0225","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.01.001_bb0230","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejim.2017.01.001_bb0235","first-page":"283","article-title":"Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care","volume":"7","author":"Guimar\u00e3es","year":"2015","journal-title":"Int J Gen Med"},{"issue":"3","key":"10.1016\/j.ejim.2017.01.001_bb0240","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11739-016-1411-0","article-title":"Why switch from warfarin to NOACs?","volume":"11","author":"Verdecchia","year":"2016","journal-title":"Intern Emerg Med"},{"issue":"3","key":"10.1016\/j.ejim.2017.01.001_bb0245","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.emc.2012.06.003","article-title":"Intracranial haemorrhage","volume":"30","author":"Caceres","year":"2012","journal-title":"Emerg Med Clin North Am"},{"issue":"4","key":"10.1016\/j.ejim.2017.01.001_bb0250","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S2352-3026(15)00027-7","article-title":"Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study","volume":"2","author":"Bouillon","year":"2015","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.ejim.2017.01.001_bb0255","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/clc.22204","article-title":"Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation","volume":"37","author":"Savelieva","year":"2014","journal-title":"Clin Cardiol"},{"issue":"21","key":"10.1016\/j.ejim.2017.01.001_bb0260","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2017.01.001_bb0265","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/eurheartj\/eht375","article-title":"Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention","volume":"35","author":"Aradi","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2017.01.001_bb0270","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12967-016-0827-7","article-title":"The lack of aspirin resistance in patients with coronary artery disease","volume":"14","author":"Homor\u00f3di","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejim.2017.01.001_bb0275","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2017.01.001_bb0280","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"ADAPT-DES investigators, platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejim.2017.01.001_bb0285","first-page":"57","article-title":"Dental management of hemorrhage-prone patients","volume":"108","author":"Szalma","year":"2015","journal-title":"Fogorv Sz"},{"issue":"10","key":"10.1016\/j.ejim.2017.01.001_bb0290","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/j.joms.2015.06.158","article-title":"Prasugrel versus clopidogrel: a comparative examination of local bleeding after dental extraction in patients receiving dual antiplatelet therapy","volume":"73","author":"D\u00e9zsi","year":"2015","journal-title":"J Oral Maxillofac Surg"},{"issue":"15","key":"10.1016\/j.ejim.2017.01.001_bb0295","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1001\/archinte.158.15.1610","article-title":"Dental surgery in anticoagulated patients","volume":"158","author":"Wahl","year":"1998","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.ejim.2017.01.001_bb0300","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/bdj.2007.892","article-title":"Guidelines for the management of patients on oral anticoagulants requiring dental surgery. British Dental Society","volume":"203","author":"Perry","year":"2007","journal-title":"Br Dent J"},{"key":"10.1016\/j.ejim.2017.01.001_bb0305","series-title":"Dental clinical guidance","article-title":"Management of dental patients taking anticoagulants or antiplatelet drugs","author":"Scottish Dental Clinical Effectiveness Programme","year":"2015"},{"key":"10.1016\/j.ejim.2017.01.001_bb0310","first-page":"166","article-title":"Anti-thrombotic therapy: implications for invasive outpatient procedures in dentistry","volume":"4","author":"Hongh","year":"2013","journal-title":"J Blood Disord Transfus"},{"issue":"2","key":"10.1016\/j.ejim.2017.01.001_bb0315","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/adj.12344","article-title":"Anticoagulant therapy and its impact on dental patients: a review","volume":"61","author":"Thean","year":"2016","journal-title":"Aust Dent J"},{"key":"10.1016\/j.ejim.2017.01.001_bb0320","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","author":"Gibson","year":"2016","journal-title":"N Engl J Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620517300018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620517300018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T03:56:25Z","timestamp":1536119785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620517300018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":63,"alternative-id":["S0953620517300018"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2017.01.001","relation":{},"ISSN":["0953-6205"],"issn-type":[{"type":"print","value":"0953-6205"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic treatment in anticoagulated atrial fibrillation patients undergoing percutaneous coronary intervention","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2017.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}